ArticleJournal of thoracic disease2026
Charting the blueprint: a bibliometric analysis reveals future strategies in lung cancer targeted therapy (2003-2025).
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress and trends on DNA methylation research in non-small cell lung cancer: a bibliometric analysis.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is recognized as one of the leading lethal malignancies worldwide. While targeted therapies have improved outcomes, a comprehensive bibliometric analysis of this dynamic field is lacking. This study aimed to systematically map the knowledge domain, hotspots, and global collaboration patterns of targeted therapy in lung cancer. Methods: Publications related to lung cancer targeted therapy between 2003 and September 2025 were retrieved through the Web of Science Core Collection. Bibliometric and visualization analyses were conducted with CiteSpace and VOSviewer. To ensure robustness, cross-validation was conducted using the Scopus database. Results: In total, 2,125 publications were identified, including 1,405 original articles and 720 reviews. The annual output showed a steady increase, with China contributing the largest volume of publications, whereas the United States and several European countries demonstrated greater citation impact and influence. Keyword and burst analyses revealed an evolution of research hotspots from classical driver mutations such as EGFR and ALK toward emerging targets including HER2, KRAS, and TROP2, as well as resistance mechanisms, immunotherapy combinations, and the tumor microenvironment. Globally, academic resources remain unevenly distributed, and international collaboration is imbalanced. Conclusions: Overall, this study elucidates the evolving knowledge structure and research trajectory of lung cancer targeted therapy, while revealing systematic disparities between research productivity, academic impact, and international collaboration across regions. Cross-validation with the Scopus database confirms the robustness of these findings, which provide a structural and evidence-based perspective to inform future research prioritization, clinical translation, and global research coordination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.